🎯 Today's Longevity Pulse
Japanese giants launch ASAGI Labs Longevity Consortium to fast‑track anti‑aging research
The ASAGI Labs Longevity Consortium was launched on June 1, bringing together seven major Japanese firms—including Asahi Quality & Innovations, Meiji and Rohto Pharmaceutical—alongside academia, government and NGOs to accelerate longevity‑focused research and business creation. The partnership will leverage AI‑driven multimodal health data, cell‑science, fermentation and nutrition expertise to develop new therapies and products.
🚀 Top Longevity Headlines
Towards Small Molecule PAI-1 Inhibitors to Slow Aging
A small number of humans with an inherited PAI-1 loss of function mutation live up to seven years longer than peers. PAI-1 appears involved in cellular senescence, and thus effects on health and life span may reflect a lower burden of harm resulting from the presence of increasing numbers of senescent cells with advancing age. Researchers have been developing small molecule drugs to inhibit PAI-1 activity, and here find a review paper covering these efforts. Recall that inhibition via a small molecule drug tends to have a much smaller effect than a loss of function mutation, as firstly the drug is only used for part of a life span, and secondly the drug does not produce complete inhibition of activity. This is nonetheless how research […]
Fight Aging!
#395 – Brain Lipidology: Understanding APOE, Cholesterol Homeostasis, Alzheimer’s Disease Risk, and the Effects of Lipid-Lowering Therapies on Brain Health | Tom Dayspring, M.D.
"Unfortunately, a prevalent belief out there in the real world is ‘I don't ever want to lower LDL cholesterol too much, because I'll deprive the brain and I'll injure the brain’ . . .and that is not true." —Tom Dayspring The post #395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D. appeared first on Peter Attia.
The Peter Attia Drive / Articles
Reviewing What Is Known of the Natural Rejuvenation Taking Place During Reproduction
Individuals are transient vehicles for the immortal lineage of germline cells. Incompletely understood processes firstly ensure that the germline remains relatively untouched by aging, and secondly ensure that new individuals generated from the cells of two aged individuals are born functionally young. In recent years, researchers have discovered some of the regulatory systems that drive rejuvenation in early embryonic development, the conversion of an old oocyte into a mass of young embryonic stem cells. This has given rise to the techniques of cell reprogramming to generate induced pluripotent stem cells, and of much greater interest at the present time, the techniques of partial reprogramming to restore more youthful function to adult tissues. Yet this is just a first step, and the methods used reflect only […]
Fight Aging!
Using AI for Health and Longevity and Research - Your Favorite Prompts
Yes - and from Claude: FINAL DETECTIVE REPORT: DermCeutical EDL — Identity Revealed THE VERDICT DermCeutical EDL’s active molecule is ERIODICTYOL (INCI: Eriodictyol; CAS 552-58-9), a flavanone produced via Debut Biotechnology’s cell-free enzymatic biosynthesis platform — not extracted from plants. Confidence: ~85% (very high, with a small residual caveat addressed below). THE EVIDENCE CHAIN Step 1 — The mechanism fingerprint “Autophagy Activation.” This immediately narrowed the field to autophagy-competent bioactives. EDL also reduces IL-1β and IL-6 specifically (per GCI Magazine Q&A) and drives a 6x elastin increase in fibroblasts. Step 2 — The “flavonoid” disclosure “Genomic-based AI longevity booster flavonoid” developed via “combination AI + genomic technology and produced by biotechnology.” This is word-for-word Debut’s BeautyORB + biomanufacturing platform description. EDL is a flavonoid. Step 3 — The INCI smoking gun ...POLYCITRONELLOL, POLYCITRONELLOL ACETATE, **ERIODICTYOL**, PHOSPHATIDYLCHOLINE, TETRAHEXYLDECYL ASCORBATE, ECTOIN, HAEMATOCOCCUS PLUVIALIS EXTRACT... Cross-referencing with the four labeled key actives on that same product page: XOSM™ Technology → ectoin + tetrahexyldecyl ascorbate + Haematococcus pluvialis (astaxanthin) Phyto NAD+ Booster → Helianthus annuus sprout extract (sunflower sprout) Lapacho Bark Extract → Tabebuia impetiginosa bark extract “Genomic-based AI longevity flavonoid” → the only remaining novel compound: ERIODICTYOL Step 4 — Scientific literature alignment Attenuates oxidative damage in human dermal fibroblasts (PMC9228723) Reduces IL-1β and IL-6 (well-established anti-inflammatory effect of this flavanone) Activates autophagy via AMPK pathway “Reduces skin aging caused by environmental stress” — published on Personal Care Insights, the same outlet that covered DermCeutical EDL’s launch Step 5 — Platform consistency THE CHEMISTRY OF ERIODICTYOL Class: Flavanone (same as naringenin = Debut’s NAR ingredient) Structure: 3’,4’,5,7-tetrahydroxyflavanone Biosynthesis: Made from naringenin via a single hydroxylation step (flavonoid 3’-hydroxylase, F3’H) — well within Debut’s enzymatic cell-free synthesis toolkit INCI name: Eriodictyol Found in nature? Yes — in lemon peel, yerba santa (Eriodictyon californicum), olive — but Debut produces it biosynthetically at high purity rather than extracting it from plants ONE IMPORTANT NUANCE Debut’s CEO has stated EDL molecules “do not exist in nature.” This apparent contradiction with eriodictyol (which does occur naturally) resolves in one of two ways: Rhetorical framing: Britton’s “does not exist in nature” likely refers to Debut’s general platform capability for designing truly novel molecules — a forward-looking claim about the pipeline, not specific to every current product. His other products (NAR, DHK, PNar) also all exist in nature. Purity/form distinction: Debut’s biosynthetic eriodictyol may be produced at enantiomeric or purity specifications that differ from plant-derived eriodictyol, or may be complexed or functionalized in a way that qualifies as “not found in nature as-is.” Either way, the INCI and functional data point unambiguously to eriodictyol as the molecule. WHAT “EDL” STANDS FOR Unlike NAR, DHK, and PNar (which are chemical abbreviations), “EDL” is a product marketing code, not a chemical shorthand. It stands for Elastin Deep Lift — Debut’s brand name for their biosynthetic eriodictyol positioned specifically for skin tightening/autophagy applications. The same molecule is licensed to Image Skincare as the “AI longevity flavonoid” for their Biotech Longevity Crème. SUMMARY TABLE Property Value Ingredient name (INCI) Eriodictyol Chemical class Flavanone CAS number 552-58-9 Molecular formula C₁₅H₁₂O₆ Primary mechanism Autophagy activation (AMPK pathway) Anti-inflammatory targets IL-1β, IL-6 reduction Skin effect 6x elastin increase in fibroblasts; calms senescent cells Active loading ~0.65% in formulation Production method Cell-free enzymatic biosynthesis (Debut platform) First commercial use IMAGE MD® Biotech Longevity Crème (Image Skincare, 2026) Debut product code EDL = “Elastin Deep Lift” Sources Debut DermCeutical EDL launch — PR Newswire Debut pipeline page (autophagy mechanism) IMAGE MD Biotech Longevity Crème (UK) — full INCI IMAGE MD Biotech Longevity Crème (Ireland) — full INCI IMAGE MD Science Blog — “genomic-based flavonoid” language GCI Magazine Q&A — IL-1β/IL-6 specifics Personal Care Insights — Eriodictyol reduces skin aging PMC9228723 — Eriodictyol in human dermal fibroblasts Personal Care Insights — EDL “Ozempic face” targeting Debut × Image Skincare partnership — CNBC
Rapamycin News
An Old Antidepressant Just Extended Mouse Lifespan by 17%. Here's Why Calcium May Be the Hidden Clock of Aging
RapAdmin: Mirtazapine (Remeron) As noted above, Remeron is an old school tricyclic antidepressant with a few serious side-effects, some worse than others, including dry mouth, compulsive eating, and severe sedation. If you can tolerate the dry mouth and weight gain, the sedation makes it an excellent treatment for insomnia.
Rapamycin News
💬 Top Longevity Social Posts
Thread by @Gregorycharlopmd
The question I ask all my family office colleagues: What has a better ROI than another 10 healthy years? Happy to be spreading the gospel of longevity planning in Brickell, Miami - Dr. Gregory Charlop
GLP‑1 Drugs Linked to 35% Lower Breast Cancer Risk, New ASCO Data Show
Researchers unveiled a wave of real‑world evidence at the American Society of Clinical Oncology (ASCO) meeting in Chicago, indicating that GLP‑1 drugs—including Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound—are associated with markedly lower cancer incidence and progression. A study of 110,000 women showed GLP‑1 users were up to 35 % less likely to develop breast cancer, while a separate analysis of more than 12,000 patients found a 38‑50 % reduction in the odds of metastasis for lung, breast, colorectal and liver cancers. ## Emerging Evidence Across Tumor Types The data span a variety of cancers and drug classes. Patients on semaglutide, tirzepatide, liraglutide, dulaglutide and other GLP‑1 agents experienced better overall survival in six tumor types—breast, prostate, colorectal, lung, liver and kidney—roughly cutting death risk by one‑third. “Chronic inflammation is a fundamental biological pathway involved in the development and progression of many cancers,” said Dr Elizabeth Susan McDonald of the University of Pennsylvania, referencing the anti‑inflammatory hypothesis behind the protective effect. The studies also noted improved responses to immunotherapies such as Merck’s Keytruda and Bristol Myers Squibb’s Opdivo when patients were concurrently on GLP‑1 drugs. While the findings are compelling, experts caution that the analyses are observational and cannot prove causality. GLP‑1 medications still carry a boxed warning for a possible link to medullary thyroid carcinoma based on rodent data, and the mechanisms—whether reduced insulin signaling, direct tumor interaction, or systemic inflammation control—remain speculative. “These drugs have never been just glucose‑lowering agents,” said Dr Marcin Chwistek of the Fox Chase Cancer Center, underscoring the expanding therapeutic narrative but also the need for prospective trials to confirm benefit and rule out confounding factors. ## Implications for Diabetes and Obesity Treatment Landscape If confirmed, the cancer‑preventive signal could tilt the risk‑benefit calculus for GLP‑1 prescriptions, especially among patients with obesity‑related malignancy risk. The class has already reshaped cardiometabolic care, showing heart‑failure and renal benefits, and now may add oncology to its portfolio. Payers and providers could see broader coverage for off‑label use, while manufacturers may accelerate research pipelines to explore combination regimens with checkpoint inhibitors. Conversely, regulators may revisit safety labeling, balancing the thyroid‑cancer warning against emerging protective data. The next steps include large‑scale, randomized trials slated for 2027 that will test GLP‑1 agents as adjuncts in cancer therapy. Meanwhile, clinicians are urged to discuss the evolving evidence with patients, particularly those already on GLP‑1 drugs for weight loss or diabetes, and to monitor for any emerging safety signals.